MDS: Unraveling the mystery

  • Rizzieri D
  • 137


    Mendeley users who have this article in their library.
  • 0


    Citations of this article.


In this issue of Blood, Sekeres et al report a phase 2 study of lenalidomide and azacitidine for higher risk myelodysplastic syndromes (MDS). High overall response and duration of response supports the concept of combination, multitargeted approaches rather than traditional chemotherapeutics for this disease.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • David A. Rizzieri

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free